These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 21738898)

  • 21. Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials.
    Karasik A; Aschner P; Katzeff H; Davies MJ; Stein PP
    Curr Med Res Opin; 2008 Feb; 24(2):489-96. PubMed ID: 18182122
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sitagliptin: profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes (update).
    Gallwitz B
    Drugs Today (Barc); 2007 Nov; 43(11):801-14. PubMed ID: 18174966
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin.
    Ahrén B
    Diabetes Metab Syndr Obes; 2010 Mar; 3():31-41. PubMed ID: 21437074
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of Miglitol, Acarbose, and Sitagliptin on Plasma Insulin and Gut Peptides in Type 2 Diabetes Mellitus: A Crossover Study.
    Ueno H; Tsuchimochi W; Wang HW; Yamashita E; Tsubouchi C; Nagamine K; Sakoda H; Nakazato M
    Diabetes Ther; 2015 Jun; 6(2):187-96. PubMed ID: 26055217
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incretin-based therapies in type 2 diabetes mellitus.
    Chia CW; Egan JM
    J Clin Endocrinol Metab; 2008 Oct; 93(10):3703-16. PubMed ID: 18628530
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of sitagliptin on glycemia, incretin hormones, and antropyloroduodenal motility in response to intraduodenal glucose infusion in healthy lean and obese humans and patients with type 2 diabetes treated with or without metformin.
    Wu T; Ma J; Bound MJ; Checklin H; Deacon CF; Jones KL; Horowitz M; Rayner CK
    Diabetes; 2014 Aug; 63(8):2776-87. PubMed ID: 24647737
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Retrospective analysis on the efficacy, safety and treatment failure group of sitagliptin for mean 10-month duration.
    Kim WJ; Park CY; Jeong EH; Seo JY; Seol JS; Park SE; Rhee EJ; Lee WY; Oh KW; Park SW; Kim SW
    Diabetes Metab J; 2011 Jun; 35(3):290-7. PubMed ID: 21785750
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.
    Pratley RE; Nauck M; Bailey T; Montanya E; Cuddihy R; Filetti S; Thomsen AB; Søndergaard RE; Davies M;
    Lancet; 2010 Apr; 375(9724):1447-56. PubMed ID: 20417856
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical pharmacokinetics and pharmacodynamics of vildagliptin.
    He YL
    Clin Pharmacokinet; 2012 Mar; 51(3):147-62. PubMed ID: 22339447
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Add-on therapy with anagliptin in Japanese patients with type-2 diabetes mellitus treated with metformin and miglitol can maintain higher concentrations of biologically active GLP-1/total GIP and a lower concentration of leptin.
    Osonoi T; Saito M; Hariya N; Goto M; Mochizuki K
    Peptides; 2016 Dec; 86():118-125. PubMed ID: 27780736
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sitagliptin with metformin: profile of a combination for the treatment of type 2 diabetes.
    Gallwitz B
    Drugs Today (Barc); 2007 Oct; 43(10):681-9. PubMed ID: 17987221
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P;
    Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Very short-term effects of the dipeptidyl peptidase-4 inhibitor sitagliptin on the secretion of insulin, glucagon, and incretin hormones in Japanese patients with type 2 diabetes mellitus: analysis of meal tolerance test data.
    Murai K; Katsuno T; Miyagawa J; Matsuo T; Ochi F; Tokuda M; Kusunoki Y; Miuchi M; Namba M
    Drugs R D; 2014 Dec; 14(4):301-8. PubMed ID: 25420579
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of single-dose DPP-4 inhibitor sitagliptin on β-cell function and incretin hormone secretion after meal ingestion in healthy volunteers and drug-naïve, well-controlled type 2 diabetes subjects.
    Alsalim W; Göransson O; Carr RD; Bizzotto R; Tura A; Pacini G; Mari A; Ahrén B
    Diabetes Obes Metab; 2018 Apr; 20(4):1080-1085. PubMed ID: 29227575
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.
    Pratley RE; Salsali A
    Curr Med Res Opin; 2007 Apr; 23(4):919-31. PubMed ID: 17407649
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term efficacy of sitagliptin as either monotherapy or add-on therapy to metformin: improvement in glycemic control over 2 years in patients with type 2 diabetes.
    Katzeff HL; Williams-Herman D; Xu L; Golm GT; Wang H; Dong Q; Johnson JR; O'Neill EA; Kaufman KD; Engel SS; Goldstein BJ
    Curr Med Res Opin; 2015 Jun; 31(6):1071-7. PubMed ID: 25850968
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Medium-Term Effect of Add-On Therapy with the DPP-4 Inhibitor, Sitagliptin, in Insulin-Treated Japanese Patients with Type 2 Diabetes Mellitus.
    Katsuno T; Ikeda H; Namba M
    Diabetes Ther; 2016 Jun; 7(2):309-20. PubMed ID: 27114254
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.